FDG in Urologic Malignancies

Poul Flemming Høilund-Carlsen; Mads Hvid Poulsen; Henrik  Petersen; Søren Hess; Lars Lund

doi:10.1016/j.cpet.2014.07.003

FDG in Urologic Malignancies

Poul Flemming Høilund-Carlsen, Mads Hvid Poulsen, Henrik Petersen, Søren Hess, Lars Lund

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Kidney, bladder, and prostate cancer account for more than one-eighth of new cancer cases worldwide. Imaging in kidney cancer is dominated by computed tomography (CT). Positron emission tomography (PET) imaging of bladder cancer is hampered by the urinary excretion of the most common PET tracer, 18F-fluoro-deoxy-glucose (FDG). PET imaging has been applied more often in prostate cancer. FDG-PET/CT is claimed to have a high frequency of false-negative results in urologic cancers; however, this finding may instead reflect correctly the state of disease being due to slow-growing cancers with a good prognosis and without a need of therapy.

Original language	English
Journal	P E T Clinics
Volume	9
Issue number	4
Pages (from-to)	457-468
ISSN	1556-8598
DOIs	https://doi.org/10.1016/j.cpet.2014.07.003
Publication status	Published - Aug 2014

Keywords

Bladder cancer
FDG
Prostate cancer
Radionuclide imaging
Renal cancer

Documents & Links

10.1016/j.cpet.2014.07.003

Cite this

@article{2ada861ca5e3466bbbfaf93911cb0aad,

title = "FDG in Urologic Malignancies",

abstract = "Kidney, bladder, and prostate cancer account for more than one-eighth of new cancer cases worldwide. Imaging in kidney cancer is dominated by computed tomography (CT). Positron emission tomography (PET) imaging of bladder cancer is hampered by the urinary excretion of the most common PET tracer, 18F-fluoro-deoxy-glucose (FDG). PET imaging has been applied more often in prostate cancer. FDG-PET/CT is claimed to have a high frequency of false-negative results in urologic cancers; however, this finding may instead reflect correctly the state of disease being due to slow-growing cancers with a good prognosis and without a need of therapy.",

keywords = "Bladder cancer, FDG, Prostate cancer, Radionuclide imaging, Renal cancer",

author = "H{\o}ilund-Carlsen, {Poul Flemming} and Poulsen, {Mads Hvid} and Henrik Petersen and S{\o}ren Hess and Lars Lund",

year = "2014",

month = aug,

doi = "10.1016/j.cpet.2014.07.003",

language = "English",

volume = "9",

pages = "457--468",

journal = "P E T Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - FDG in Urologic Malignancies

AU - Høilund-Carlsen, Poul Flemming

AU - Poulsen, Mads Hvid

AU - Petersen, Henrik

AU - Hess, Søren

AU - Lund, Lars

PY - 2014/8

Y1 - 2014/8

N2 - Kidney, bladder, and prostate cancer account for more than one-eighth of new cancer cases worldwide. Imaging in kidney cancer is dominated by computed tomography (CT). Positron emission tomography (PET) imaging of bladder cancer is hampered by the urinary excretion of the most common PET tracer, 18F-fluoro-deoxy-glucose (FDG). PET imaging has been applied more often in prostate cancer. FDG-PET/CT is claimed to have a high frequency of false-negative results in urologic cancers; however, this finding may instead reflect correctly the state of disease being due to slow-growing cancers with a good prognosis and without a need of therapy.

AB - Kidney, bladder, and prostate cancer account for more than one-eighth of new cancer cases worldwide. Imaging in kidney cancer is dominated by computed tomography (CT). Positron emission tomography (PET) imaging of bladder cancer is hampered by the urinary excretion of the most common PET tracer, 18F-fluoro-deoxy-glucose (FDG). PET imaging has been applied more often in prostate cancer. FDG-PET/CT is claimed to have a high frequency of false-negative results in urologic cancers; however, this finding may instead reflect correctly the state of disease being due to slow-growing cancers with a good prognosis and without a need of therapy.

KW - Bladder cancer

KW - FDG

KW - Prostate cancer

KW - Radionuclide imaging

KW - Renal cancer

U2 - 10.1016/j.cpet.2014.07.003

DO - 10.1016/j.cpet.2014.07.003

M3 - Journal article

SN - 1556-8598

VL - 9

SP - 457

EP - 468

JO - P E T Clinics

JF - P E T Clinics

IS - 4

ER -

FDG in Urologic Malignancies

Abstract

Keywords

Documents & Links

Fingerprint

Cite this